EP1015006A4 - COCOA EXTRACT COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE - Google Patents

COCOA EXTRACT COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE

Info

Publication number
EP1015006A4
EP1015006A4 EP97929671A EP97929671A EP1015006A4 EP 1015006 A4 EP1015006 A4 EP 1015006A4 EP 97929671 A EP97929671 A EP 97929671A EP 97929671 A EP97929671 A EP 97929671A EP 1015006 A4 EP1015006 A4 EP 1015006A4
Authority
EP
European Patent Office
Prior art keywords
making
methods
same
cocoa extract
extract compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97929671A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1015006A2 (en
Inventor
Leo J Romanczyk Jr
John F Hammerstone Jr
Margaret M Buck
Laurie S Post
Giovanni G Cipolla
Craig A Mcclelland
Jeff A Mundt
Harold H Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1996/004497 external-priority patent/WO1997036597A1/en
Application filed by Mars Inc filed Critical Mars Inc
Priority to EP08020626A priority Critical patent/EP2110134A1/en
Publication of EP1015006A2 publication Critical patent/EP1015006A2/en
Publication of EP1015006A4 publication Critical patent/EP1015006A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
EP97929671A 1996-04-02 1997-04-02 COCOA EXTRACT COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE Ceased EP1015006A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08020626A EP2110134A1 (en) 1996-04-02 1997-04-02 Cocoa extract compounds and methods for making and using the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63166196A 1996-04-02 1996-04-02
US631661 1996-04-02
PCT/US1996/004497 WO1997036597A1 (en) 1996-04-02 1996-04-02 Cocoa extract compounds and methods for making and using the same
WOPCT/US96/04497 1996-04-02
PCT/US1997/005693 WO1997036497A2 (en) 1996-04-02 1997-04-02 Cocoa extract compounds and methods for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08020626A Division EP2110134A1 (en) 1996-04-02 1997-04-02 Cocoa extract compounds and methods for making and using the same

Publications (2)

Publication Number Publication Date
EP1015006A2 EP1015006A2 (en) 2000-07-05
EP1015006A4 true EP1015006A4 (en) 2003-09-24

Family

ID=26790948

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97929671A Ceased EP1015006A4 (en) 1996-04-02 1997-04-02 COCOA EXTRACT COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE
EP08020626A Withdrawn EP2110134A1 (en) 1996-04-02 1997-04-02 Cocoa extract compounds and methods for making and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08020626A Withdrawn EP2110134A1 (en) 1996-04-02 1997-04-02 Cocoa extract compounds and methods for making and using the same

Country Status (9)

Country Link
EP (2) EP1015006A4 (enExample)
JP (2) JP2000506901A (enExample)
CN (1) CN1159019C (enExample)
AU (1) AU742198B2 (enExample)
BR (1) BR9710955A (enExample)
CA (1) CA2250792C (enExample)
PL (1) PL329325A1 (enExample)
RU (1) RU2010111103A (enExample)
WO (1) WO1997036497A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696485B1 (en) 1996-04-02 2004-02-24 Mars, Incorporated Procyanidin and cyclo-oxygenase modulator compositions
US7968140B2 (en) 1997-09-08 2011-06-28 Mars, Incorporated Chocolates and chocolate liquor having an enhanced polyphenol content
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
US6207842B1 (en) * 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
AU2004200273B2 (en) * 1998-03-12 2008-02-07 Mars, Incorporated Products Containing Polyphenol(s) and L-Arginine to stimulate nitric oxide production
US8507018B2 (en) 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
RU2269268C2 (ru) * 1998-03-12 2006-02-10 Марс, Инкорпорейтед Продукты, содержащие полифенол(ы) и l-аргинин, для стимуляции продукции окиси азота
US7011856B2 (en) * 1998-08-05 2006-03-14 Amino Up Chemical Co., Ltd. Composition for the treatment of symptoms and conditions associated with aging
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000054792A1 (en) * 1999-03-17 2000-09-21 Morinaga & Co., Ltd. Drugs, foods, drinks and feeds containing cocoa component
JP3260134B2 (ja) 1999-10-08 2002-02-25 信孝 鈴木 月経困難症、子宮内膜症の治療薬
US6524630B2 (en) * 2000-03-22 2003-02-25 Mars, Incorporated Use of cocoa procyanidins combined with acelylsalicyclic acid as an anti-platelet therapy
WO2001078529A2 (en) * 2000-04-14 2001-10-25 Mars, Incorporated Compositions and methods for improving vascular health
US6627232B1 (en) * 2000-06-09 2003-09-30 Mars Incorporated Method for extracting cocoa procyanidins
DE10037983B4 (de) 2000-08-03 2006-04-13 Stefan Zikeli Polymerzusammensetzung und daraus hergestellter Formkörper mit einem Gehalt an Alkaloid
FR2812873B1 (fr) 2000-08-11 2003-08-01 Barry Callebaut France Procede de production de polyphenols a partir de feves de cacao
JP4763139B2 (ja) * 2001-02-21 2011-08-31 株式会社アミノアップ化学 新規な多価フェノール重合体及びその用途
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) * 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
FR2838055B1 (fr) * 2002-04-05 2006-06-09 Cep Nouvelle utilisation d'un extrait de cacao et les compositions cosmetiques et/ou dermatologiques a cet effet
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US8945518B2 (en) 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
CA2484192C (en) 2002-04-30 2012-10-02 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
KR20030097398A (ko) * 2002-06-21 2003-12-31 이노천 양념육용 폴리페놀을 함유한 소스
US20040220119A1 (en) 2003-04-04 2004-11-04 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
TWI279231B (en) * 2003-10-02 2007-04-21 Asahi Breweries Ltd Neutralization agent of vacuolization toxin
JP2007508316A (ja) * 2003-10-10 2007-04-05 マーズ　インコーポレイテッド ＥｒｂＢ２キナーゼ過剰発現に関連する病気の治療
AU2005209317B2 (en) * 2004-01-28 2011-07-07 Mars, Incorporated Compositions and methods of use of A-type procyanidins
CA2599295C (en) * 2005-02-25 2014-10-14 Nagasaki University Method of producing proanthocyanidin oligomer
JP4681363B2 (ja) * 2005-03-04 2011-05-11 美智士 谷 悪性腫瘍治療剤及びそれを含む飲食品
JP4942953B2 (ja) * 2005-06-30 2012-05-30 サントリーホールディングス株式会社 プロシアニジンの分析方法
KR100761248B1 (ko) 2006-10-12 2007-10-04 주식회사 유니젠 대나무 및 황금 추출물을 유효성분으로 함유하는 아토피성피부염 치료를 위한 조성물
US8609174B2 (en) 2006-11-17 2013-12-17 Barry Callebaut Ag Method for producing a soluble cocoa product from cocoa powder
ES2401926T3 (es) 2006-11-17 2013-04-25 Barry Callebaut Ag Método para la producción de un producto de cacao soluble a partir de cacao en polvo
GB0724716D0 (en) 2007-12-19 2008-01-30 Barry Callebaut Ag Process
GB0801119D0 (en) 2008-01-22 2008-02-27 Barry Callebaut Ag Composition
FR2927811B1 (fr) * 2008-02-27 2010-09-10 Unither Dev Colorant pharmaceutique extrait de cranberry concentre en proanthocyanidines a.
JP5462491B2 (ja) * 2009-01-21 2014-04-02 株式会社 エフェクト プロアントシアニジン三量体
CN102414312A (zh) 2009-04-03 2012-04-11 戴安娜植物科学有限公司 从植物细胞培养物中生产和抽提原花青素
US9167840B2 (en) 2009-04-03 2015-10-27 DianaPlantScience, Inc. Production and extraction of procyanidins from plant cell cultures
JP5569716B2 (ja) * 2009-06-23 2014-08-13 独立行政法人国立循環器病研究センター レクチン様酸化ｌｄｌ受容体阻害用医薬品
CN102933569A (zh) * 2009-12-17 2013-02-13 新加坡国立大学 表儿茶素衍生物/低聚物的制备方法及其应用
JP5801327B2 (ja) 2010-03-05 2015-10-28 マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ カカオ抽出物を含む美味しい飲料および組成物
WO2012078797A1 (en) * 2010-12-07 2012-06-14 The Hershey Company Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products
AU2012214104C1 (en) * 2011-02-08 2017-08-03 Poly Gain Pte Ltd Sugar extracts
WO2013121608A1 (ja) * 2012-02-16 2013-08-22 株式会社カマタ カプセル内蔵フィルターとこのフィルターを備えたタバコ及びタバコ代用品
ITTV20120064A1 (it) * 2012-04-19 2013-10-20 R I Group Srl Estratto per trattamento delle cefalee primitive
CN103113384B (zh) * 2013-02-27 2015-05-20 安徽农业大学 一种名为茯砖素b的儿茶素类衍生物及其制备方法和应用
WO2016046375A1 (en) * 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders
TW201733605A (zh) * 2016-02-29 2017-10-01 明治股份有限公司 可可水萃物、含它之飲食品、可可萃取物之製造方法、及多酚之萃取方法
EP3747276B1 (en) 2019-06-04 2024-11-06 ODC Lizenz AG Cocoa-based frozen desserts and methods of their manufacture

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1584725A (enExample) * 1968-01-30 1970-01-02
JPS5832875A (ja) * 1981-07-30 1983-02-25 Nippon Shinyaku Co Ltd タンニン
JPS58154571A (ja) * 1982-03-08 1983-09-14 Nippon Shinyaku Co Ltd 新規タンニン
US4698360A (en) * 1985-04-09 1987-10-06 Societe Civile D'investigations Pharmacologiques D'aquitaine Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US4704292A (en) * 1984-12-10 1987-11-03 Cacaofabriek De Zaan B.V. Cocoa
US4797421A (en) * 1984-07-03 1989-01-10 Kikkoman Corporation Antioxidant comprising proanthocyanidin as principal component
EP0301975A2 (fr) * 1987-07-30 1989-02-01 Martine Andrée Bonnaure-Mallet Monomère et/ou oligomère procyanidolique pour le traitement de maladies parodontales
US4863956A (en) * 1985-07-19 1989-09-05 Inverni Della Beffa Spa Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use
WO1994029404A1 (fr) * 1993-06-14 1994-12-22 Berkem Compositions de derives de polyphenols et leur preparation
WO1996010404A1 (en) * 1994-10-03 1996-04-11 Mars, Incorporated Antineoplastic cocoa extracts, methods for making, using
WO1996030033A1 (en) * 1995-03-24 1996-10-03 Jlb, Inc. Method of treating or preventing non-viral microbial infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575004A (en) * 1976-03-23 1980-09-17 Iverni Della Beffa Spa Pharmacologically active polyphenolic substances
JPS6425726A (en) * 1987-04-24 1989-01-27 Yuutoku Yakuhin Kogyo Kk Agent for eliminating active oxygen free radical
CA2128293C (en) * 1993-12-06 2002-09-03 Masayuki Tanabe Fruit polyphenols and medicinal compositions containing them

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1584725A (enExample) * 1968-01-30 1970-01-02
JPS5832875A (ja) * 1981-07-30 1983-02-25 Nippon Shinyaku Co Ltd タンニン
JPS58154571A (ja) * 1982-03-08 1983-09-14 Nippon Shinyaku Co Ltd 新規タンニン
US4797421A (en) * 1984-07-03 1989-01-10 Kikkoman Corporation Antioxidant comprising proanthocyanidin as principal component
US4704292A (en) * 1984-12-10 1987-11-03 Cacaofabriek De Zaan B.V. Cocoa
US4698360A (en) * 1985-04-09 1987-10-06 Societe Civile D'investigations Pharmacologiques D'aquitaine Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US4863956A (en) * 1985-07-19 1989-09-05 Inverni Della Beffa Spa Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use
EP0301975A2 (fr) * 1987-07-30 1989-02-01 Martine Andrée Bonnaure-Mallet Monomère et/ou oligomère procyanidolique pour le traitement de maladies parodontales
WO1994029404A1 (fr) * 1993-06-14 1994-12-22 Berkem Compositions de derives de polyphenols et leur preparation
WO1996010404A1 (en) * 1994-10-03 1996-04-11 Mars, Incorporated Antineoplastic cocoa extracts, methods for making, using
WO1996030033A1 (en) * 1995-03-24 1996-10-03 Jlb, Inc. Method of treating or preventing non-viral microbial infection

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AN B-J ET AL: "STRUCTURE DETERMINATION OF GLUCOSYLTRANSFERASE INHIBITORS FROM CACAO BEAN HUSK", AGRICULTURAL CHEMISTRY AND BIOTECHNOLOGY, XX, KR, vol. 6, no. 37, 1994, pages 498 - 502, XP001087855, ISSN: 1229-2737 *
CHENG, JUEI TANG ET AL: "Antihypertensive principles from the leaves of Melastoma candidum", PLANTA MED. ( 1993 ), 59(5), 405-7, XP001088259 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OTSUKA, HIROSHI ET AL: "Studies on antiinflammatory agents. VI. Antiinflammatory constituents of Cinnamomum sieboldii Meissn", XP002248248, retrieved from STN Database accession no. 96:223079 HCA *
HONG, CHUANG-YE ET AL: "The inhibitory effect of tannins on lipid peroxidation of rat heart mitochondria", J. PHARM. PHARMACOL. ( 1995 ), 47(2), 138-42, XP001087938 *
KOLODZIEJ, H. ET AL: "Moderate cytotoxicity of proanthocyanidins to human tumor cell lines", PHYTOTHER. RES. ( 1995 ), VOLUME DATE 1995, 9(6), 410-15, XP001088174 *
PORTER L J ET AL: "CACAO PROCYANIDINS: MAJOR FLAVANOIDS AND IDENTIFICATION OF SOME MINOR METABOLITES", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 5, no. 30, 1991, pages 1657 - 1663, XP001084175, ISSN: 0031-9422 *
ROHRBACH M S ET AL: "STRUCTURAL DETERMINANTS OF THE PLATELET AGONIST ACTIVITY OF COTTON BRACT CONDENSED TANNIN", ENVIRONMENTAL RESEARCH, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 52, no. 2, August 1990 (1990-08-01), pages 199 - 209, XP002166001, ISSN: 0013-9351 *
See also references of WO9736497A3 *
VENNAT B ET AL: "PROCYANIDINS FROM THE ROOTS OF FRAGARIA VESCA: CHARACTERIZATION AND PHARMACOLOGICAL APPROACH", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 2, no. 36, February 1988 (1988-02-01), pages 828 - 833, XP001087909, ISSN: 0009-2363 *
YAKUGAKU ZASSHI (1982), 102(2), 162-72 *

Also Published As

Publication number Publication date
AU3367497A (en) 1997-10-22
HK1020881A1 (en) 2000-05-26
BR9710955A (pt) 2001-03-13
PL329325A1 (en) 1999-03-29
AU742198B2 (en) 2001-12-20
JP2000506901A (ja) 2000-06-06
CA2250792C (en) 2011-09-13
WO1997036497A2 (en) 1997-10-09
RU2010111103A (ru) 2011-09-27
EP2110134A1 (en) 2009-10-21
EP1015006A2 (en) 2000-07-05
JP2011006427A (ja) 2011-01-13
CN1159019C (zh) 2004-07-28
WO1997036497A3 (en) 1997-12-24
CN1221344A (zh) 1999-06-30
CA2250792A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
EP1015006A4 (en) COCOA EXTRACT COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE
IL127032A0 (en) A solid clear composition and a method for preparing the same
GB9622665D0 (en) Methods
AU5711696A (en) Cocoa extract compounds and methods for making and using the same
GB2330515B (en) Alternative cigarette and method for preparing the same
GB9619758D0 (en) Method
GB9605709D0 (en) Method
GB9625686D0 (en) Tapered speeddeck
TW391621U (en) Electro-magentic roaster
PL332278A1 (en) Novel methods
GB9616563D0 (en) Compounds and methods
GB9600117D0 (en) Extractor
GB9605482D0 (en) Method
GB2310190B (en) Liquid-foaming insert
EP0934345A4 (en) CONNECTIONS AND PROCEDURE
GB9711545D0 (en) Insert
GB9619759D0 (en) Method
PL303077A1 (en) Biohumus extract
GB9723384D0 (en) Microflora
HU9600340V0 (en) Coffee-maker
AU762P (en) CARMELLA Argyranthemum frutescens
GB9615383D0 (en) Extraction dedvice
PL316317A1 (en) Herb composition
PL317267A1 (en) Herb preparation
GB9604875D0 (en) Styrocrete et al

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981028

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 35/78 A, 7A 61K 31/35 B, 7A 61K 31/705 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 35/78 A, 7A 61K 31/35 B, 7A 61K 31/705 B, 7A 61P 9/00 B, 7A 61P 29/00 B, 7A 61P 31/04 B, 7A 61P 35/00 B

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61P 31/04 B

Ipc: 7A 61P 29/00 B

Ipc: 7A 61P 9/00 B

Ipc: 7A 61K 31/704 B

Ipc: 7A 61K 31/353 B

Ipc: 7A 61K 35/78 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030807

17Q First examination report despatched

Effective date: 20031118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081128